References
Adriani KS, Brouwer MC, Geldhoff M, Baas F, Zwinderman AH, Paul Morgan
B, et al. (2013). Common polymorphisms in the complement system
and susceptiblity to bacterial meningitis. J Infect 66:255-262.
Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, et
al. (2001). Identification of a selective nonpeptide antagonist of the
anaphylatoxin C3a receptor that demonstrates antiinflammatory activity
in animal models. J Immunol 166: 6341-6348.
An P, Saenz Robles MT, Duray AM, Cantalupo PG, & Pipas JM (2019). Human
polyomavirus BKV infection of endothelial cells results in interferon
pathway induction and persistence. PLoS Pathog 15: e1007505.
Antoniou K, Ender F, Vollbrandt T, Laumonnier Y, Rathmann F, Pasare
C, et al. (2020). Allergen-Induced C5a/C5aR1 Axis Activation in
Pulmonary CD11b(+) cDCs Promotes Pulmonary Tolerance through
Downregulation of CD40. Cells 9.
Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer
C, et al. (2016). T helper 1 immunity requires complement-driven
NLRP3 inflammasome activity in CD4(+) T cells. Science 352:aad1210.
Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, Kohl J, et
al. (2013). C3a modulates IL-1beta secretion in human monocytes by
regulating ATP efflux and subsequent NLRP3 inflammasome activation.
Blood 122: 3473-3481.
Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen
KK, et al. (2009). Race and socioeconomic status influence
outcomes of unrelated donor hematopoietic cell transplantation. Biol
Blood Marrow Transplant 15: 1543-1554.
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J,
Crawford JM, et al. (2020). Targeting potential drivers of
COVID-19: Neutrophil extracellular traps. J Exp Med 217.
Belford A, Myles O, Magill A, Wang J, Myhand RC, & Waselenko JK (2004).
Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6
(HHV-6) reactivation in an adult receiving high-dose melphalan with
autologous peripheral stem cell transplantation. Am J Hematol
76: 156-162.
Bernig T, Taylor JG, Foster CB, Staats B, Yeager M, & Chanock SJ
(2004). Sequence analysis of the mannose-binding lectin (MBL2) gene
reveals a high degree of heterozygosity with evidence of selection.
Genes Immun 5: 461-476.
Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, et al.(2007). Studies on the interactions between C-reactive protein and
complement proteins. Immunology 121: 40-50.
Bitzan M, & Zieg J (2018). Influenza-associated thrombotic
microangiopathies. Pediatr Nephrol 33: 2009-2025.
Borosss P, Yildiz C, Simons PJ, Boon L, & Hack CE (2016). A monoclonal
antibody against complement C2 as a novel inhibitor. In Atlant
Conference 2016:Innate Host Defence. Utrecht, The Netherlands.
Bouts A, Monnens L, Davin JC, Struijk G, & Spanjaard L (2011).
Insufficient protection by Neisseria meningitidis vaccination alone
during eculizumab therapy. Pediatr Nephrol 26: 1919-1920.
Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, et al. (2004).
Sensitive and specific monoclonal antibody-based capture enzyme
immunoassay for detection of nucleocapsid antigen in sera from patients
with severe acute respiratory syndrome. J Clin Microbiol 42:2629-2635.
Chen L, Li X, Chen M, Feng Y, & Xiong C (2020). The ACE2 expression in
human heart indicates new potential mechanism of heart injury among
patients infected with SARS-CoV-2. Cardiovasc Res.
Chen S, Lu D, Zhang M, Che J, Yin Z, Zhang S, et al. (2005).
Double-antigen sandwich ELISA for detection of antibodies to
SARS-associated coronavirus in human serum. Eur J Clin Microbiol Infect
Dis 24: 549-553.
Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, et
al. (2010). Genome-wide association study identifies variants in the
CFH region associated with host susceptibility to meningococcal disease.
Nat Genet 42: 772-776.
Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A,
et al. (2020). Eculizumab treatment in patients with COVID-19:
preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev
Med Pharmacol Sci 24: 4040-4047.
Dobo J, Szakacs D, Oroszlan G, Kortvely E, Kiss B, Boros E, et
al. (2016). MASP-3 is the exclusive pro-factor D activator in resting
blood: the lectin and the alternative complement pathways are
fundamentally linked. Sci Rep 6: 31877.
Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E, et
al. (2002). Cytolytically inactive terminal complement complex causes
transendothelial migration of polymorphonuclear leukocytes in vitro and
in vivo. Blood 99: 185-192.
Ekdahl KN, Mohlin C, Adler A, Aman A, Manivel VA, Sandholm K, et
al. (2019). Is generation of C3(H2O) necessary for activation of the
alternative pathway in real life? Mol Immunol 114: 353-361.
Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, et
al. (2016). Dangerous liaisons: complement, coagulation, and
kallikrein/kinin cross-talk act as a linchpin in the events leading to
thromboinflammation. Immunol Rev 274: 245-269.
el-Lati SG, Dahinden CA, & Church MK (1994). Complement peptides C3a-
and C5a-induced mediator release from dissociated human skin mast cells.
J Invest Dermatol 102: 803-806.
Fischer WH, & Hugli TE (1997). Regulation of B cell functions by C3a
and C3a(desArg): suppression of TNF-alpha, IL-6, and the polyclonal
immune response. J Immunol 159: 4279-4286.
Fischer WH, Jagels MA, & Hugli TE (1999). Regulation of IL-6 synthesis
in human peripheral blood mononuclear cells by C3a and C3a(desArg). J
Immunol 162: 453-459.
Fox SE, Akmatbekov A, Harbert JL, Li G, Brown Q, & Vander Heide RS
(2020). Pulmonary and cardiac pathology in COVID-19: the first autopsy
series from New Orleans: medRxiv.
Fukuoka Y, & Hugli TE (1988). Demonstration of a specific C3a receptor
on guinea pig platelets. J Immunol 140: 3496-3501.
Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu
Y, et al. (2017). Long lasting neutralization of C5 by SKY59, a
novel recycling antibody, is a potential therapy for complement-mediated
diseases. Sci Rep 7: 1080.
Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. (2020). Highly
pathogenic coronavirus N protein aggravates lung injury by
MASP-2.mediated complement over-activation. doi: doi:
https://doi.org/10.1101/2020.03.29.20041962
Garcia CC, Weston-Davies W, Russo RC, Tavares LP, Rachid MA, Alves-Filho
JC, et al. (2013). Complement C5 activation during influenza A
infection in mice contributes to neutrophil recruitment and lung injury.
PLoS One 8: e64443.
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z,
et al. (2011). Netting neutrophils are major inducers of type I IFN
production in pediatric systemic lupus erythematosus. Sci Transl Med
3: 73ra20.
Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ,
et al. (2016). A journey through the lectin pathway of complement-MBL
and beyond. Immunol Rev 274: 74-97.
Garred P, J JS, Quist L, Taaning E, & Madsen HO (2003). Association of
mannose-binding lectin polymorphisms with sepsis and fatal outcome, in
patients with systemic inflammatory response syndrome. J Infect Dis
188: 1394-1403.
Garred P, Larsen F, Seyfarth J, Fujita R, & Madsen HO (2006).
Mannose-binding lectin and its genetic variants. Genes Immun 7:85-94.
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, & Chiumello D
(2020). Covid-19 Does Not Lead to a ”Typical” Acute Respiratory Distress
Syndrome. Am J Respir Crit Care Med.
Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou
A, Antonakos N, et al. (2020). Complex Immune Dysregulation in
COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe.
Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh R, et
al. (2020). Thinking beyond HLH: clinical features of patients with
concurrent presentation of hemophagocytic lymphohistiocytosis and
thrombotic microangiopathy. Biol Blood Marrow Transplant 26:S15-S16.
Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder
MN, et al. (2017). Circulating dsDNA, endothelial injury, and
complement activation in thrombotic microangiopathy and GVHD. Blood
130: 1259-1266.
Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, & Christiani DC
(2007). Polymorphisms in the mannose binding lectin-2 gene and acute
respiratory distress syndrome. Crit Care Med 35: 48-56.
Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura JI, Nunn
MA, et al. (2017). Use of the complement inhibitor Coversin to
treat HSCT-associated TMA. Blood Adv 1: 1254-1258.
Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist
SR, et al. (2018). Complement Activation Contributes to Severe
Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 9.
Guan M, Chen HY, Foo SY, Tan YJ, Goh PY, & Wee SH (2004). Recombinant
protein-based enzyme-linked immunosorbent assay and
immunochromatographic tests for detection of immunoglobulin G antibodies
to severe acute respiratory syndrome (SARS) coronavirus in SARS
patients. Clin Diagn Lab Immunol 11: 287-291.
Guglietta S, Chiavelli A, Zagato E, Krieg C, Gandini S, Ravenda
PS, et al. (2016). Coagulation induced by C3aR-dependent NETosis
drives protumorigenic neutrophils during small intestinal tumorigenesis.
Nat Commun 7: 11037.
Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, & Woodruff TM (2017).
New concepts on the therapeutic control of complement anaphylatoxin
receptors. Mol Immunol 89: 36-43.
Hayashi M, Machida T, Ishida Y, Ogata Y, Omori T, Takasumi M, et
al. (2019). Cutting Edge: Role of MASP-3 in the Physiological
Activation of Factor D of the Alternative Complement Pathway. J Immunol
203: 1411-1416.
Hellemann D, Larsson A, Madsen HO, Bonde J, Jarlov JO, Wiis J, et
al. (2007). Heterozygosity of mannose-binding lectin (MBL2) genotypes
predicts advantage (heterosis) in relation to fatal outcome in intensive
care patients. Hum Mol Genet 16: 3071-3080.
Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendorf AM, Baensch
M, et al. (1999). Selection of a C5a receptor antagonist from
phage libraries attenuating the inflammatory response in immune complex
disease and ischemia/reperfusion injury. J Immunol 163:985-994.
Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de
Cordoba S, Morgan BP, et al. (2011). Common polymorphisms in C3,
factor B, and factor H collaborate to determine systemic complement
activity and disease risk. Proc Natl Acad Sci U S A 108:8761-8766.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen
S, et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and
TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. (2005).
Mannose-binding lectin in severe acute respiratory syndrome coronavirus
infection. J Infect Dis 191: 1697-1704.
Jager U, D’Sa S, Schorgenhofer C, Bartko J, Derhaschnig U, Sillaber
C, et al. (2019). Inhibition of complement C1s improves severe
hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Blood 133: 893-901.
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton
P, et al. (2017). Randomized Trial of C5a Receptor Inhibitor
Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol 28:2756-2767.
Jiang Y, Li J, Teng Y, Sun H, Tian G, He L, et al. (2019).
Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in
hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses 11.
Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, et al. (2018).
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic
mice infected with MERS-CoV. Emerg Microbes Infect 7: 77.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson
A, et al. (2016a). Terminal Complement Blockade after
Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal
Vaccination. Biol Blood Marrow Transplant 22: 1337-1340.
Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC,
et al. (2020a). Complement blockade for TA-TMA: lessons learned from a
large pediatric cohort treated with eculizumab. Blood 135:1049-1057.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al.(2014). Diagnostic and risk criteria for HSCT-associated thrombotic
microangiopathy: a study in children and young adults. Blood
124: 645-653.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et
al. (2016b). Variable Eculizumab Clearance Requires Pharmacodynamic
Monitoring to Optimize Therapy for Thrombotic Microangiopathy after
Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant
22: 307-315.
Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin
BL, et al. (2020b). Interferon-complement loop in
transplant-associated thrombotic microangiopathy. Blood Adv 4:1166-1177.
Jodele S, Zhang K, Dandoy CE, Myers KC, Lane A, & Davies SM (2017).
Donor genotype and susceptibility to transplant-associated thrombotic
microangiopathy. Biol Blood Marrow Transplant 03.
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al.(2016c). The genetic fingerprint of susceptibility for
transplant-associated thrombotic microangiopathy. Blood 127:989-996.
Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, et al.(2016). Structural basis for therapeutic inhibition of complement C5.
Nat Struct Mol Biol 23: 378-386.
Karasu E, Nilsson B, Kohl J, Lambris JD, & Huber-Lang M (2019).
Targeting Complement Pathways in Polytrauma- and Sepsis-Induced
Multiple-Organ Dysfunction. Front Immunol 10: 543.
Karsten CM, & Kohl J (2012). The immunoglobulin, IgG Fc receptor and
complement triangle in autoimmune diseases. Immunobiology 217:1067-1079.
Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, & Kohl J (2009). The
role of the anaphylatoxins in health and disease. Mol Immunol
46: 2753-2766.
Kordowski A, Reinicke AT, Wu D, Orinska Z, Hagemann P, Huber-Lang
M, et al. (2019). C5a receptor 1(-/-) mice are protected from the
development of IgE-mediated experimental food allergy. Allergy
74: 767-779.
Kretzschmar T, Jeromin A, Gietz C, Bautsch W, Klos A, Kohl J, et
al. (1993). Chronic myelogenous leukemia-derived basophilic
granulocytes express a functional active receptor for the anaphylatoxin
C3a. Eur J Immunol 23: 558-561.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R,
Gonzalez-Fernandez FA, et al. (2019). Ravulizumab (ALXN1210) vs
eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302
study. Blood 133: 540-549.
Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S,
et al. (2019). The natural history of BK polyomavirus and the host
immune response after stem cell transplantation. Clin Infect Dis.
Laumonnier Y, Karsten CM, & Kohl J (2017). Novel insights into the
expression pattern of anaphylatoxin receptors in mice and men. Mol
Immunol 89: 44-58.
Lazar HL, Keilani T, Fitzgerald CA, Shapira OM, Hunter CT, Shemin
RJ, et al. (2007). Beneficial effects of complement inhibition
with soluble complement receptor 1 (TP10) during cardiac surgery: is
there a gender difference? Circulation 116: I83-88.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S,
Fureder W, et al. (2019). Ravulizumab (ALXN1210) vs eculizumab in
adult patients with PNH naive to complement inhibitors: the 301 study.
Blood 133: 530-539.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C,
et al. (2013). Terminal complement inhibitor eculizumab in atypical
hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181.
Levi M, Cohn DM, & Zeerleder S (2019). Hereditary angioedema: Linking
complement regulation to the coagulation system. Res Pract Thromb
Haemost 3: 38-43.
Lipworth B, Chan R, Lipworth S, & RuiWen Kuo C (2020). Weathering the
cytokine storm in susceptible patients with severe SARS-CoV-2 infection.
J Allergy Clin Immunol Pract.
Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. (2020).
Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting
antibodies against SARS-CoV-2. J Clin Microbiol.
Lounder DT, Bin Q, de Min C, & Jordan MB (2019). Treatment of
refractory hemophagocytic lymphohistiocytosis with emapalumab despite
severe concurrent infections. Blood Adv 3: 47-50.
Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et
al. (1995). Interplay between promoter and structural gene variants
control basal serum level of mannan-binding protein. J Immunol
155: 3013-3020.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et
al. (2020). Complement associated microvascular injury and thrombosis
in the pathogenesis of severe COVID-19 infection: A report of five
cases. Transl Res.
Mastellos DC, Ricklin D, & Lambris JD (2019). Clinical promise of
next-generation complement therapeutics. Nat Rev Drug Discov
18: 707-729.
[Online] Available from
https://clinicaltrials.gov/ct2/results?cond=Thrombotic+Microangiopathies&term=OMS721&cntry=&state=&city=&dist=&Search=Search.
[Accessed: 042020 2020].
[Online] Available from
https://www.clinicaltrials.gov/ct2/show/NCT03347396?term=NCT03347396&rank=1.
[Accessed].
Meliopoulos VA, Karlsson EA, Kercher L, Cline T, Freiden P, Duan
S, et al. (2014). Human H7N9 and H5N1 influenza viruses differ in
induction of cytokines and tissue tropism. J Virol 88:12982-12991.
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky
AL, et al. (2014). Genetic variants in C5 and poor response to
eculizumab. N Engl J Med 370: 632-639.
Ohta R, Torii Y, Imai M, Kimura H, Okada N, & Ito Y (2011). Serum
concentrations of complement anaphylatoxins and proinflammatory
mediators in patients with 2009 H1N1 influenza. Microbiol Immunol
55: 191-198.
Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL, et al.(2004). C5a mutants are potent antagonists of the C5a receptor (CD88)
and of C5L2: position 69 is the locus that determines agonism or
antagonism. J Biol Chem 279: 142-151.
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. (2020).
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
its immune cross-reactivity with SARS-CoV. Nat Commun 11: 1620.
Paun CC, Lechanteur YTE, Groenewoud JMM, Altay L, Schick T, Daha
MR, et al. (2016). A Novel Complotype Combination Associates with
Age-Related Macular Degeneration and High Complement Activation Levels
in vivo. Sci Rep 6: 26568.
Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al.(2003). Clinical progression and viral load in a community outbreak of
coronavirus-associated SARS pneumonia: a prospective study. Lancet
361: 1767-1772.
Reid RC, Yau MK, Singh R, Hamidon JK, Reed AN, Chu P, et al.(2013). Downsizing a human inflammatory protein to a small molecule with
equal potency and functionality. Nat Commun 4: 2802.
Ricklin D, Mastellos DC, Reis ES, & Lambris JD (2018). The renaissance
of complement therapeutics. Nat Rev Nephrol 14: 26-47.
Ricklin D, Reis ES, Mastellos DC, Gros P, & Lambris JD (2016).
Complement component C3 - The ”Swiss Army Knife” of innate immunity and
host defense. Immunol Rev 274: 33-58.
Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath
CJ, et al. (2012). The complement receptor 2/factor H fusion
protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes
from complement-mediated hemolysis and C3 fragment. Blood 119:6307-6316.
Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay
CR, et al. (2008). Functional roles for C5a receptors in sepsis.
Nat Med 14: 551-557.
Rowley JA, Reid RC, Poon EKY, Wu KC, Lim J, Lohman RJ, et al.(2020). Potent Thiophene Antagonists of Human Complement C3a Receptor
with Anti-Inflammatory Activity. J Med Chem 63: 529-541.
Sahu A, Kay BK, & Lambris JD (1996). Inhibition of human complement by
a C3-binding peptide isolated from a phage-displayed random peptide
library. J Immunol 157: 884-891.
Schindler R, Gelfand JA, & Dinarello CA (1990). Recombinant C5a
stimulates transcription rather than translation of interleukin-1 (IL-1)
and tumor necrosis factor: translational signal provided by
lipopolysaccharide or IL-1 itself. Blood 76: 1631-1638.
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, et
al. (2013). Rational engineering of a minimized immune inhibitor with
unique triple-targeting properties. J Immunol 190: 5712-5721.
Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. (2020).
Proteomic and Metabolomic characterization of COVID-19 patient sera.
doi: doi: https://doi.org/10.1101/2020.04.07.20054585
Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et
al. (2014). TNT003, an inhibitor of the serine protease C1s, prevents
complement activation induced by cold agglutinins. Blood 123:4015-4022.
Steffensen R, Thiel S, Varming K, Jersild C, & Jensenius JC (2000).
Detection of structural gene mutations and promoter polymorphisms in the
mannan-binding lectin (MBL) gene by polymerase chain reaction with
sequence-specific primers. J Immunol Methods 241: 33-42.
Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, & Bemelman FJ
(2013). Meningococcal sepsis complicating eculizumab treatment despite
prior vaccination. Am J Transplant 13: 819-820.
Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, et al. (2015).
Treatment with anti-C5a antibody improves the outcome of H7N9 virus
infection in African green monkeys. Clin Infect Dis 60:586-595.
Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, et al. (2013).
Inhibition of complement activation alleviates acute lung injury induced
by highly pathogenic avian influenza H5N1 virus infection. Am J Respir
Cell Mol Biol 49: 221-230.
Thye T, Niemann S, Walter K, Homolka S, Intemann CD, Chinbuah MA,
et al. (2011). Variant G57E of mannose binding lectin associated with
protection against tuberculosis caused by Mycobacterium africanum but
not by M. tuberculosis. PLoS One 6: e20908.
Tu X, Chong WP, Zhai Y, Zhang H, Zhang F, Wang S, et al. (2015).
Functional polymorphisms of the CCL2 and MBL genes cumulatively increase
susceptibility to severe acute respiratory syndrome coronavirus
infection. J Infect 71: 101-109.
Umemura M, Miwa Y, Yanai R, Isojima S, Tokunaga T, Tsukamoto H, et
al. (2015). A case of Degos disease: demonstration of C5b-9-mediated
vascular injury. Mod Rheumatol 25: 480-483.
[Online] Available from
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
[Accessed].
Vallurupalli M, & Berliner N (2019). Emapalumab for the treatment of
relapsed/refractory hemophagocytic lymphohistiocytosis. Blood
134: 1783-1786.
Wang R, Xiao H, Guo R, Li Y, & Shen B (2015). The role of C5a in acute
lung injury induced by highly pathogenic viral infections. Emerg
Microbes Infect 4: e28.
Weaver DJ, Jr., Reis ES, Pandey MK, Kohl G, Harris N, Gerard C, et
al. (2010). C5a receptor-deficient dendritic cells promote induction of
Treg and Th17 cells. Eur J Immunol 40: 710-721.
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA,
et al. (2020). Virological assessment of hospitalized patients with
COVID-2019. Nature.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. (2020).
Pathological findings of COVID-19 associated with acute respiratory
distress syndrome. Lancet Respir Med 8: 420-422.
Yabe H, Hattori K, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, et
al. (2005). Fatal adenovirus infection indistinguishable from
thrombotic microangiopathy after allogeneic CD34+ peripheral progenitor
cell transplantation. Tokai J Exp Clin Med 30: 71-75.
Yuan FF, Tanner J, Chan PK, Biffin S, Dyer WB, Geczy AF, et al.(2005). Influence of FcgammaRIIA and MBL polymorphisms on severe acute
respiratory syndrome. Tissue Antigens 66: 291-296.
Yuen J, Pluthero FG, Douda DN, Riedl M, Cherry A, Ulanova M, et
al. (2016). NETosing Neutrophils Activate Complement Both on Their Own
NETs and Bacteria via Alternative and Non-alternative Pathways. Front
Immunol 7: 137.
Zareei N, Miri HR, Karimi MH, Afshari A, Geramizadeh B, Roozbeh J,
et al. (2019). Increasing of the interferon-gamma gene expression
during polyomavirus BK infection in kidney transplant patients. Microb
Pathog 129: 187-194.
Zhang H, Zhou G, Zhi L, Yang H, Zhai Y, Dong X, et al. (2005).
Association between mannose-binding lectin gene polymorphisms and
susceptibility to severe acute respiratory syndrome coronavirus
infection. J Infect Dis 192: 1355-1361.
Zhao M (2020). Cytokine storm and immunomodulatory therapy in COVID-19:
role of chloroquine and anti-IL-6 monoclonal antibodies. Int J
Antimicrob Agents: 105982.
Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, et
al. (2010). A single asparagine-linked glycosylation site of the severe
acute respiratory syndrome coronavirus spike glycoprotein facilitates
inhibition by mannose-binding lectin through multiple mechanisms. J
Virol 84: 8753-8764.